



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07D 403/02, 413/02, 411/02, 419/02, 417/02, A61K 31/495</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/07701</b> <b>(43) International Publication Date:</b> 18 February 1999 (18.02.99)
<b>(21) International Application Number:</b> PCT/US98/16232 <b>(22) International Filing Date:</b> 4 August 1998 (04.08.98) <b>(30) Priority Data:</b> 60/054,903                      5 August 1997 (05.08.97)                      US 60/059,686                      19 September 1997 (19.09.97)                      US <b>(71) Applicant:</b> SUGEN, INC. [US/US]; 351 Galveston Drive, Redwood City, CA 94063 (US). <b>(72) Inventors:</b> TANG, Peng, Cho; 827 Camino Ricardo, Moraga, CA 94556 (US). McMAHON, Gerald; 1800 Schultz Road, Kenwood, CA 95452 (US). <b>(74) Agents:</b> ROSE, Bernard, F. et al.; Lyon & Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>With amended claims.</i>
<b>(54) Title:</b> TRICYCLIC QUINOXALINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS <b>(57) Abstract</b> <p>The present invention relates to tricyclic quinoxaline compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein tyrosine kinases and therefore should be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.</p>		



























































































































































































































































































































